Minerva Neurosciences Inc Stock News
$3.97
2.22%
day before yesterday
Nasdaq,
Dec 24, 07:00 pm CET
Minerva Neurosciences Inc Stock News
Neutral
GlobeNewsWire
●
about one month ago
Dr. Inder Kaul, CMO of Draig Therapeutics, joins Minerva Neuroscience Board of Directors, and will also serve as a consultant for roluperidone development.
Neutral
GlobeNewsWire
●
about 2 months ago
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2025 ending September 30, 2025.
Neutral
GlobeNewsWire
●
2 months ago
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone's clinical development and NDA resubmission.
Neutral
GlobeNewsWire
●
4 months ago
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
